journal article·2023-06Open access

IL‐1β Is an Androgen‐Responsive Target in Macrophages for Immunotherapy of Prostate Cancer

Deng Wang, Chaping Cheng, Xinyu Chen, Jinming Wang, Kaiyuan Liu, Na Jing, Penghui Xu, Xialian Xi, Yujiao Sun, Zhongzhong Ji, Huifang Zhao, Yuman He, Kai Zhang, Xinxing Du, Baijun Dong, Yuxiang Fang, Pengcheng Zhang, Xueming Qian, Wei Xue, Wei‐Qiang Gao, Helen He Zhu

Advanced Science· Volume 10· Issue 17

Abstract

Abstract Great attention is paid to the role of androgen receptor (AR) as a central transcriptional factor in driving the growth of prostate cancer (PCa) epithelial cells. However, the understanding of the role of androgen in PCa‐infiltrated immune cells and the impact of androgen deprivation therapy (ADT), the first‐line treatment for advanced PCa, on the PCa immune microenvironment remains limited. On the other hand, immune checkpoint blockade has revolutionized the treatment of certain cancer types, but fails to achieve any benefit in advanced PCa, due to an immune suppressive environment. In this study, it is reported that AR signaling pathway is evidently activated in tumor‐associated macrophages (TAMs) of PCa both in mice and humans. AR acts as a transcriptional repressor for IL1B in TAMs. ADT releases the restraint of AR on IL1B and therefore leads to an excessive expression and secretion of IL‐1β in TAMs. IL‐1β induces myeloid‐derived suppressor cells (MDSCs) accumulation that inhibits the activation of cytotoxic T cells, leading to the immune suppressive microenvironment. Critically, anti‐IL‐1β antibody coupled with ADT and the immune checkpoint inhibitor anti‐PD‐1 antibody exerts a stronger anticancer effect on PCa following castration. Together, IL‐1β is an important androgen‐responsive immunotherapeutic target for advanced PCa.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Immunotherapy and Immune Responses · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oncogenes and Related Genes Renji‐Med‐X Stem Cell Research Center Shanghai Cancer Institute & Department of Urology Ren Ji Hospital School of Medicine and School of Biomedical Engineering Shanghai Jiao Tong University Shanghai 200127 P. R. China

School of Biomedical Engineering and Med‐X Research Institute Shanghai Jiao Tong University Shanghai 200030 P. R. China

Department of Urology Ren Ji Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200127 P. R. China

School of Biomedical Engineering ShanghaiTech University Shanghai 201210 P. R. China

Mabspace Biosciences (Suzhou) Co. Limited Suzhou 215123 P. R. China

Funding

National Natural Science Foundation of China · Program of Shanghai Academic Research Leader · Science and Technology Commission of Shanghai Municipality

References (70)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1001/jama.2017.724810.1001/jama.2017.7248 ↗
3. 10.1038/nrc401610.1038/nrc4016 ↗
4. 10.1038/nrurol.2018.2210.1038/nrurol.2018.22 ↗
5. 10.1038/aps.2014.1810.1038/aps.2014.18 ↗
6. 10.1210/er.2002-003210.1210/er.2002-0032 ↗
7. 10.1073/pnas.080470110510.1073/pnas.0804701105 ↗
8. 10.1172/JCI9915910.1172/JCI99159 ↗
9. 10.1016/j.canlet.2020.10.03110.1016/j.canlet.2020.10.031 ↗
10. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
11. 10.1158/2159-8290.CD-18-036710.1158/2159-8290.CD-18-0367 ↗
12. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
13. 10.1038/s41391-021-00340-510.1038/s41391-021-00340-5 ↗
14. 10.1038/s41591-021-01600-610.1038/s41591-021-01600-6 ↗
15. 10.1016/j.xcrm.2022.10061310.1016/j.xcrm.2022.100613 ↗
16. 10.1038/nm.446310.1038/nm.4463 ↗
17. 10.1038/s41586-018-0266-010.1038/s41586-018-0266-0 ↗
18. 10.1186/s40164-021-00252-z10.1186/s40164-021-00252-z ↗
19. 10.1172/JCI4586210.1172/JCI45862 ↗
20. 10.1084/jem.2010195610.1084/jem.20101956 ↗
21. 10.1084/jem.2008217310.1084/jem.20082173 ↗
22. 10.1016/j.immuni.2014.06.01010.1016/j.immuni.2014.06.010 ↗
23. 10.1111/imr.1262110.1111/imr.12621 ↗
24. 10.1016/j.immuni.2013.11.01010.1016/j.immuni.2013.11.010 ↗
25. 10.1038/nrrheum.2010.410.1038/nrrheum.2010.4 ↗
26. 10.1016/j.ccr.2008.10.01110.1016/j.ccr.2008.10.011 ↗
27. 10.1038/nature1428210.1038/nature14282 ↗
28. 10.1038/nature0391810.1038/nature03918 ↗
29. 10.1038/ng.265010.1038/ng.2650 ↗
30. 10.1038/s42003-020-01476-110.1038/s42003-020-01476-1 ↗
31. 10.1093/annonc/mdx68910.1093/annonc/mdx689 ↗
32. 10.1073/pnas.190265111610.1073/pnas.1902651116 ↗
33. 10.1016/j.cell.2018.03.02210.1016/j.cell.2018.03.022 ↗
34. 10.1038/s41467-020-18313-y10.1038/s41467-020-18313-y ↗
35. 10.1126/sciimmunol.aay601710.1126/sciimmunol.aay6017 ↗
36. 10.1038/s41591-018-0136-110.1038/s41591-018-0136-1 ↗
37. 10.1038/s43018-021-00227-310.1038/s43018-021-00227-3 ↗
38. 10.1126/scitranslmed.aad565910.1126/scitranslmed.aad5659 ↗
39. 10.1038/s41586-022-04522-610.1038/s41586-022-04522-6 ↗
40. 10.1016/j.immuni.2022.07.01610.1016/j.immuni.2022.07.016 ↗
41. 10.1126/sciimmunol.abq263010.1126/sciimmunol.abq2630 ↗
42. 10.1073/pnas.140246811110.1073/pnas.1402468111 ↗
43. 10.1158/0008-5472.CAN-14-096010.1158/0008-5472.CAN-14-0960 ↗
44. 10.1158/0008-5472.CAN-17-136610.1158/0008-5472.CAN-17-1366 ↗
45. 10.3390/cancers1207179110.3390/cancers12071791 ↗
46. 10.1158/1078-0432.CCR-20-161010.1158/1078-0432.CCR-20-1610 ↗
47. 10.1158/1078-0432.CCR-03-030010.1158/1078-0432.CCR-03-0300 ↗
48. 10.1016/j.ejca.2003.08.01110.1016/j.ejca.2003.08.011 ↗
49. 10.1038/onc.2009.24710.1038/onc.2009.247 ↗
50. 10.1073/pnas.181226611510.1073/pnas.1812266115 ↗
51. 10.3390/cancers304385610.3390/cancers3043856 ↗
52. 10.1016/j.ctrv.2018.06.00510.1016/j.ctrv.2018.06.005 ↗
53. 10.3390/cancers903002110.3390/cancers9030021 ↗
54. 10.1038/s41591-020-01168-710.1038/s41591-020-01168-7 ↗
55. 10.1158/1078-0432.CCR-12-332710.1158/1078-0432.CCR-12-3327 ↗
56. 10.1200/JCO.2016.71.349510.1200/JCO.2016.71.3495 ↗
57. 10.1002/hep.2971510.1002/hep.29715 ↗
58. 10.1126/scitranslmed.300114310.1126/scitranslmed.3001143 ↗
59. 10.1053/j.gastro.2008.05.04610.1053/j.gastro.2008.05.046 ↗
60. 10.1002/hep.2047410.1002/hep.20474 ↗
61. 10.1016/j.canlet.2019.05.01910.1016/j.canlet.2019.05.019 ↗
62. 10.1038/nature2167610.1038/nature21676 ↗
63. 10.1158/1535-7163.MCT-11-026410.1158/1535-7163.MCT-11-0264 ↗
64. 10.1007/978-3-319-91442-8_510.1007/978-3-319-91442-8_5 ↗
65. 10.1158/1535-7163.MCT-09-016010.1158/1535-7163.MCT-09-0160 ↗
66. 10.1634/theoncologist.2016-014510.1634/theoncologist.2016-0145 ↗
67. 10.1111/cpr.1305610.1111/cpr.13056 ↗
68. 10.1016/j.ccell.2017.09.00310.1016/j.ccell.2017.09.003 ↗
69. L.McInnes J.Healy J. J. A. E.‐P.Melville arXiv:1802.034262018.
70. 10.1006/cimm.1996.011310.1006/cimm.1996.0113 ↗